5 November 2025 in Science Translational Medicine
Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non–AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8 + T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8 + T cell–dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1 + PD-1 + Tim-3 − stem-like memory CD8 + T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8 + T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8 + T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8 + T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.
8 August 2025 in PLOS Pathogens
The persistence of HIV-1 reservoirs during combination anti-retroviral therapy (cART) is associated with chronic inflammation and systemic immune activation in people infected with HIV-1 (PWH), leading to a suboptimal immune reconstitution as well as an increased risk of non-AIDS events. In this study, we assessed the effect of CD24-Fc, a fusion protein with anti-inflammatory properties that interacts with danger-associated molecular patterns (DAMPs) and siglec-10, in humanized mice with chronic HIV-1 infection under suppressive cART in vivo and in peripheral blood mononuclear cells (PBMCs) from PWH in vitro. We report that CD24-Fc treatment significantly reduced inflammation and immune hyperactivation in humanized mice with HIV-1 infection and cART. CD24-Fc treatment improved recovery of CD4 T cells, reduced immune hyper-activation, increased functional central memory T cells. Notably, CD24-Fc treatment increased CXCR5 + CD8 central memory T cells (TCM) with increased HIV-specific polyfunctionality in humanized mice and in PBMC from PWH. This enhanced anti-HIV T cell activity was associated with improved control of HIV-1 viral rebound and reduced HIV-1 pathogenesis upon cART cessation. Our findings indicate that CD24-Fc may provide a promising new therapeutic for treating chronic inflammation and associated diseases in PWH.
2 November 2026 in HIV Medicine
Objectives: HIV perturbs T cell homeostasis and disrupts immune function, increasing the risk of age‐associated comorbidities. Ageing people with HIV (PWH) have exacerbated expression of CD38 on T cells, which depletes intracellular nicotinamide adenine dinucleotide (NAD+). We investigated whether boosting intracellular NAD+ could restore T cell homeostasis and function. Methods: We collected blood samples from virally suppressed PWH to determine the effects of in vitro NAD+ on CD38 expression and T cell function in response to anti‐CD3/CD28 antibodies stimulation in PBMCs culture supplemented with IL‐2 and IL‐7. Results: We observed that NAD+ supplementation not only reduced expression of CD38 but also improved T cell function with an alleviated exhaustion phenotype in response to anti‐CD3/CD28 antibodies stimulation. Conclusions: If confirmed in clinical trials, NAD+ supplementation has the potential to restore T cell homeostasis and immune function in PWH and ameliorate age‐associated comorbidities.
19 June 2026 in Journal of Biological Chemistry
Immune-stimulating antibody conjugates (ISACs) represent an emerging class of immunotherapeutics that combine tumor-targeted antibodies with innate immune agonists. However, current ISAC platforms often rely on heterogeneous conjugation strategies and poorly defined antibody architectures, making it difficult to disentangle how Fc glycosylation, payload presentation, and linker design collectively govern immune activation. Here we report a dual-enzymatic antibody editing strategy that integrates Fc glyco-engineering with site-specific payload conjugation to construct structurally defined immune-stimulating antibody conjugates. Using microbial transglutaminase-mediated conjugation at the Fc Q295 residue together with Endo-S2-mediated Fc glycan remodeling at N297, we generated trastuzumab-based ISACs with defined Fc glycoforms and linker architectures. Systematic evaluation reveals that Fc glycosylation state and payload presentation act as orthogonal and synergistic determinants of immune activation. In particular, an intact and afucosylated Fc glycan is essential for robust tumor-cell killing and cytokine induction, while cleavable linkers further enhance innate immune activation through efficient intracellular release of the TLR7/8 agonist. This work establishes a versatile chemical strategy for controlling antibody architecture and immune activation, providing a broadly applicable platform for the rational design of next-generation antibody therapeutics.